Early clinical development program, including results of a first-in-human trial of LIB-01, a novel, first in class potential oral erectile dysfunction drug with unique pharmacodynamic properties


ne and rance

François Giuliano	AP-HP, Neuro-Uro-Andrology, Dept. of Physical Medicin Rehabilitation, Raymond Poincaré hospital, Garches, Fr
Harin Padma-Nathan	Independent consultant
Raymond Rosen	UCSF School of Medicine
Christopher Forest	Dominican University of California
Mats Holmberg	ANOVA, Karolinska University Hospital
Charlotta Gauffin	Dicot Pharma

LIB-01: A novel and first-in-class small molecule (*phragmalin-type limonoid*) for ED


Phase 1 Design

- Safety following single (SAD, N=40) and multiple ascending dosing (MAD, N=24)
- ED participants in MAD part of trial (age18-65 and IIEF-EF score 11-25 for inclusion)
- 3-day dosing; 25mg QD, 25mg BID, 50mg QD or Placebo
- 28 days follow up
- Exploratory efficacy:
 - IIEF-EF and Real-time RigiScan®



Results

- Improved erectile function by IIEF-EF domain score mean change 7.8
- Increased erectile rigidity by RigiScan[®]
- At least 28 days duration of pro erectile effect
- Safety few, mild, and self-limited GI symptoms on day one



IIEF-EF mean score

Phase 2a Ongoing

Phase 2a Design

- Safety and Efficacy of LIB-01 in treatment of ED "Proof of Concept"
- 140 male ED participants in (age 25-65 and IIEF-EF score 11-25 for inclusion)
- Six sites in EU (Sweden, Denmark, Netherlands)
- 3-day dosing; LIB-01 (three dose levels) or Placebo
- 8 weeks follow up
- Efficacy:
 - Primary: IIEF-EF on Week 4
 - SEP questions 2 (Were you able to insert your penis into your partner's vagina?) and 3 (Did your erection last long enough for you to have successful intercourse?) throughout the trial period



Conclusions LIB 01

Phase 1

- Safe and well tolerated
- Improved erectile function demonstrated by IIEF-EF and RigiScan[®]
- Duration of pro erectile effect of at least 28 days following a 3-day dosing
- This new molecule has the potential to dramatically change the paradigm of ED management
- Phase 2a results expected in mid-2025